2
N2O2 group and the presence of two different conformers of
also detected by HPLC. At pH 7.4, 0.5 moles of N2O were
produced along with 0.3 moles of NO per mole of 2b
dissociated. These reactions are summarized in Scheme 2.
Comparable results were observed on hydrolysis of 2c and
2d.
2b along with two water molecules in the asymmetric unit that
forms a hydrogen bonded helix (Fig. 1). Similar results were
obtained on nitrosation of the p-nitrophenyl analogue 1d;
although the structure of the diazeniumdiolate product 2d did
not refine well (R = 0.125), this was due to disorder in the
crystal which could not be modelled in the refinement. The
atomic connectivity and atom assignments are, however, well
defined.¶
Since nitrosation of all four N-hydroxyguanidines 1a–d
yields hydrolytically unstable products with ultraviolet maxima
near 320 nm that generate significant quantities of NO in neutral
buffer, the crystallographic data for products 2b and 2d strongly
suggest that the ‘nitric oxide carrier’ seen by Hecker et al.4 on
exposing 1a to aerobic NO was diazeniumdiolate 2a.
We postulate that our data may be of two-fold biological
significance. First, if free 1a can be shown to encounter suitably
nitrosating conditions in vivo, the product 2a would constitute a
naturally occurring diazeniumdiolate that spontaneously re-
leases NO at physiological pH; two other natural products
containing the diazeniumdiolate functional group, dopastin and
alanosine, have been reported to release NO only on one-
electron oxidation.11 Second, the NO-generating properties of
compounds 2 may render them useful as prodrugs for treating
clinical disorders arising from deficiencies of biosynthetic NO.1
The possible medicinal value of 2 and analogous structures will
be investigated.
Rapid measurement of the ultraviolet spectrum on dissolution
of 2b in water permitted quantitative determination of the
characteristic chromophore’s extinction coefficient (2.5 mm21
cm21 at lmax = 322 nm). The NMR spectrum, run at 250 °C
in CD3OD–tetramethylsilane to minimize the rapid decomposi-
tion observed at room temperature, consisted of singlets for the
CH3O and CH2 protons at d 3.77 and 4.57, respectively, and an
aryl AAABBA pattern with shifts of d 6.93 and 7.30 (ortho and
meta to OCH3, respectively) and J = 8.6, 2.7, and 0.4 Hz for the
ortho, meta and para couplings, respectively. The mass spectra
of 2b and 2d were unusual (but not unprecedented) in their
failure to produce an observable MH+ ion in either the
electrospray or fast atom bombardment modes; strong peaks
due to the respective benzyl cations were seen in both cases, but
15N-labelling indicated that the terminal NO was rapidly lost
even under the mildest possible electrospray conditions.
Compound 2b was found to decompose with gas evolution on
dissolution in aqueous media. At pH 10, N-(p-methoxy-
benzyl)cyanamide 3b and N2O were each produced in !95%
yield in a relatively slow reaction (half-life at 37 °C variable but
estimated as 15–25 min) that is presumably initiated by
deprotonation of the NH2 group followed by loss of cis-
hyponitrite (2O–NNN–O2), a known progenitor of N2O.8
Compound 2b tended to disappear more rapidly as pH was
lowered, with a half-life at pH 3 of about 5 min; some
denitrosation was observed at very low pH, 1b being the most
abundant of the organic products seen in 0.1 m HCl. The major
gaseous product at low pH proved to be NO, reaching yields of
0.9 moles per mole of 2b at pH 3 compared with 0.25 moles of
N2O. While the mechanism of NO formation is not clear at this
time, there can be little doubt about its production; its identity
was confirmed both by the presence of its aqueous autoxidation
product, nitrite ion,9 in the reaction mixture and by a well-
established, highly selective chemiluminescence method.10 In
physiological buffer (10 mm phosphate, pH 7.4), N-(p-
methoxybenzyl)urea 4b was produced in 90% yield, with 8%
conversion to 3b and a small amount of an unidentified product
Notes and References
† Present address: Inotek Inc., 3rd Floor, 3130 Highland Avenue,
Cincinnati, OH 45219-2374, USA.
‡ E-mail: gjsouthan@aol.com
§ Crystal data for 2b. C9H12N4O3·H2O, Mr = 242.24, monoclinic space
group P21, a = 12.452(2), b = 7.156(1), c = 12.887(2) Å, b = 97.74(1)°,
V = 1137.8(3) Å3, Z = 4, Dc = 1.414 Mg m23, l(Mo- Ka) = 0.71073 Å,
m = 0.113 mm21, F(000) = 512, T = 223 K. A set of 1773 reflections was
collected, and 1388 were observed with Fo > 4s(Fo), R1 = 0.034 and wR2
= 0.083.
¯
¶ Crystals were triclinic, space group P1, a = 6.256(1), b = 7.120(3), c =
13.180(2) Å, a = 95.11(1), b = 92.33(1), g = 106.01(1)°. CCDC 182/839.
1 L. K. Keefer, C .F. Nathan and W. J. Payne, in Encyclopedia of
Molecular Biology and Molecular Medicine, ed. R .A. Meyers, VCH,
Weinheim, 1996, vol. 4, p. 200.
2 D. A. Wink, M. B. Grisham, J. B. Mitchell and P. C. Ford, Methods
Enzymol., 1996, 268, 12.
3 D. I. Simon, M. E. Mullins, L. Jia, B. Gaston, D. J. Singel and J. S.
Stamler, Proc. Natl. Acad. Sci. USA, 1996, 93, 4736.
4 M. Hecker, H. Macarthur, W. C. Sessa, G. J. Southan, T. A. Swierkosz,
D. T. Walsh, A. Zembowicz and J. R. Vane, in The Biology of Nitric
Oxide. 2. Enzymology, Biochemistry and Immunology, ed. S. Moncada,
M. A. Marletta, J. B. Hibbs, Jr. and E. A. Higgs, Portland Press, London,
1992, p. 128.
RHN CN
5 A. Zembowicz, T. A. Swierkosz, G. J. Southan, M. Hecker and J. R.
Vane, Br. J. Pharmacol., 1992, 107, 1001.
3b
6 M. Hecker, M. Boese, V. B. Schini-Kerth, A. Mu¨lsch and R. Busse,
Proc. Natl. Acad. Sci. USA, 1995, 92, 4671.
7 D. L. H. Williams, Nitrosation, Cambridge University Press, Cam-
bridge, 1988.
8 J. Yoo and J. M. Fukuto, Biochem. Pharmacol., 1995, 50, 1995. These
authors have proposed 2 as a possible intermediate (postulated to form
on coupling of an oxidatively generated N-hydroxyguanidine radical
cation with NO) in the slow reaction of hydroxyguanidines with
anaerobic NO.
O–
2H+
N2O + H2O
N
O–
pH 10
N
H2N
+ C
RHN
O–
N
H2N
pH 7.4
N
+ N2O + NO
O
C
O
RHN
2b
4b
9 L. J. Ignarro, J. M. Fukuto, J. M. Griscavage, N. E. Rogers and R. E.
Byrns, Proc. Natl. Acad. Sci. USA, 1993, 90, 8103.
0.1 M HCl
H2N
10 M. Feelisch and E. A. Noack, Eur. J. Pharmacol., 1987, 142, 465; C. M.
Maragos, D. Morley, D. A. Wink, T. M. Dunams, J. E. Saavedra, A.
Hoffman, A. A. Bove, L. Isaac, J. A. Hrabie and L. K. Keefer, J. Med.
Chem., 1991, 34, 3242.
C
NOH
+ HONO
RHN
1b
11 T. A. Alston, D. J. T. Porter and H. J. Bright, J. Biol. Chem., 1985, 260,
4069.
R =
MeO
CH2
Scheme 2
Received in Corvallis, OR, USA, 23rd February 1998; 8/01543K
1192
Chem. Commun., 1998